Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Martínez, M.
Right arrow Articles by Patterson, T. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Martínez, M.
Right arrow Articles by Patterson, T. F.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (2002) 49, 515-524
© 2002 The British Society for Antimicrobial Chemotherapy

Heterogeneous mechanisms of azole resistance in Candida albicans clinical isolates from an HIV-infected patient on continuous fluconazole therapy for oropharyngeal candidosis

M. Martíneza, J. L. López-Ribota,*, W. R. Kirkpatricka, S. P. Bachmanna, S. Pereaa, M. T. Ruesgab and T. F. Pattersona,c

a Department of Medicine, Division of Infectious Diseases, The University of Texas Health Science Center, South Texas Centers for Biology in Medicine, San Antonio, TX; c Audie Murphy Division, South Texas Veterans Health Care System, San Antonio, TX, USA; b Departamento de Inmunología, Microbiología y Parasitología, Facultad de Medicina y Odontología, Universidad del País Vasco, Lejona, Vizcaya, Spain

Molecular mechanisms of azole resistance in Candida albicans include alterations in the target enzyme and increased efflux of drug, but the impact of specific treatment regimens on resistance has not been established. A patient with advanced AIDS was enrolled in a longitudinal study to receive continuous oral fluconazole (FLU) 200 mg/day for the treatment of oropharyngeal candidosis (OPC). Oral cultures were obtained at time of enrolment, during episodes of OPC and quarterly for surveillance. The patient had five symptomatic relapses on continuous FLU during 43 months. All OPC episodes were successfully treated with increasing doses of FLU although increased FLU MICs were detected for C. albicans isolates with progression of time. DNA-typing techniques demonstrated that resistance developed in a persistent strain of C. albicans. Both FLU-resistant and isogenic isolates with reduced susceptibility were detected in the same clinical samples through multiple episodes. Analysis of molecular mechanisms of resistance revealed overexpression of MDR and CDR genes encoding efflux pumps (but not ERG11) in isolates with decreased FLU susceptibility. In addition, the presence of the G464S amino acid substitution in their lanosterol demethylase, affecting its affinity for FLU, was also detected. However, other isogenic, but FLU-susceptible isolates recovered from the same samples did not harbour the mutation, indicating microevolution of yeast populations within the oral cavity. In this patient, the continuous antifungal pressure exerted by FLU resulted in development of resistance of multifactorial nature. Despite their clonal origin, different subpopulations of C. albicans demonstrated distinct resistance mechanisms, including concomitant presence and absence of functional point mutations in ERG11 genes.

* Corresponding author. Tel: +1-210-562-5017; Fax: +1-210-562-5016; E-mail: ribot{at}uthscsa.edu


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Clin. Microbiol.Home page
B. D. Alexander, T. C. Byrne, K. L. Smith, K. E. Hanson, K. J. Anstrom, J. R. Perfect, and L. B. Reller
Comparative Evaluation of Etest and Sensititre YeastOne Panels against the Clinical and Laboratory Standards Institute M27-A2 Reference Broth Microdilution Method for Testing Candida Susceptibility to Seven Antifungal Agents
J. Clin. Microbiol., March 1, 2007; 45(3): 698 - 706.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
J. B. Harry, B. G. Oliver, J. L. Song, P. M. Silver, J. T. Little, J. Choiniere, and T. C. White
Drug-Induced Regulation of the MDR1 Promoter in Candida albicans
Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2785 - 2792.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
K. S. Barker, S. Crisp, N. Wiederhold, R. E. Lewis, B. Bareither, J. Eckstein, R. Barbuch, M. Bard, and P. D. Rogers
Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans
J. Antimicrob. Chemother., August 1, 2004; 54(2): 376 - 385.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
M.-K. Lee, L. E. Williams, D. W. Warnock, and B. A. Arthington-Skaggs
Drug resistance genes and trailing growth in Candida albicans isolates
J. Antimicrob. Chemother., February 1, 2004; 53(2): 217 - 224.
[Abstract] [Full Text] [PDF]


Home page
Antimicrob. Agents Chemother.Home page
L. Rodero, E. Mellado, A. C. Rodriguez, A. Salve, L. Guelfand, P. Cahn, M. Cuenca-Estrella, G. Davel, and J. L. Rodriguez-Tudela
G484S Amino Acid Substitution in Lanosterol 14-{alpha} Demethylase (ERG11) Is Related to Fluconazole Resistance in a Recurrent Cryptococcus neoformans Clinical Isolate
Antimicrob. Agents Chemother., November 1, 2003; 47(11): 3653 - 3656.
[Abstract] [Full Text] [PDF]


Home page
J Antimicrob ChemotherHome page
N. Bodasing, R. A. Seaton, G. S. Shankland, and A. Pithie
Gamma-interferon treatment for resistant oropharyngeal candidiasis in an HIV-positive patient
J. Antimicrob. Chemother., November 1, 2002; 50(5): 765 - 766.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.